Neuropeptide S vs Pemvidutide
Head-to-head comparison of Neuropeptide S (Neuropeptide S) and Pemvidutide (Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Neuropeptide S | Pemvidutide |
|---|---|---|
| Category | Cognitive Enhancement | Weight Management |
| Full Name | Neuropeptide S | Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 2203 Da | N/A |
| Half-Life | Minutes to <1 hour | Approximately 1 week |
| Amino Acids | 20 | N/A |
| Typical Dose | Research-only; no validated human dose | Trial-dependent; once-weekly SC titration |
| Route | Intracerebroventricular/Intranasal | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 28 | 18 |
| Research Status | Pre-clinical | Clinical |
Neuropeptide S Benefits
- ✓anxiolysis
- ✓stress resilience
- ✓attention support
- ✓arousal modulation
Pemvidutide Benefits
- ✓appetite suppression
- ✓body-weight reduction
- ✓improved liver-fat markers
- ✓better glycemic control
Neuropeptide S Dosing
0.1-1 nmol i.c.v. in animal studies|intranasal research-only exploration|no established human protocol
Pemvidutide Dosing
once-weekly subcutaneous injection|gradual dose escalation|maintenance at tolerated trial dose
Neuropeptide S Side Effects
- ⚠sleep disruption
- ⚠headache
- ⚠jitteriness
Pemvidutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Neuropeptide S
Animal studies suggest NPS can reduce anxiety-like behavior while altering wakefulness and alertness through the NPS receptor system. Human cognitive data are very limited, and it has no approved clinical indication.
Pemvidutide
Clinical studies have reported dose-dependent weight loss and favorable effects on liver fat and transaminases. It remains investigational and is not approved for obesity treatment.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.